Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Gsk Plc (GSK.LN)

Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Is This a Setback for Moderna? Motley Fool - Tue May 14, 5:35AM CDT

Moderna's shares slipped after the company announced the delay.

PFE : 28.64 (-0.97%)
GSK.LN : 1,775.000 (-0.48%)
MRNA : 132.90 (+0.17%)
Drug Patents
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition Associated Press - Tue Apr 30, 4:36PM CDT

The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic

AZN.LN : 12,110.002 (-0.46%)
AZN : 76.90 (-0.18%)
GSK.LN : 1,775.000 (-0.48%)
GSK : 44.98 (+0.22%)
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. Motley Fool - Tue Apr 9, 5:35AM CDT

These companies are close to launching new products that could supercharge revenue.

LLY : 770.00 (-0.15%)
PFE : 28.64 (-0.97%)
GSK.LN : 1,775.000 (-0.48%)
MRNA : 132.90 (+0.17%)
VRTX : 445.21 (+1.04%)
RSV Drug
Babies should get recently approved drug for RSV, CDC says Associated Press - Thu Aug 3, 2023

U.S. health officials are recommending that babies get a recently approved drug to protect them against a respiratory virus

PFE : 28.64 (-0.97%)
GSK.LN : 1,775.000 (-0.48%)
GSK : 44.98 (+0.22%)
AZN.LN : 12,110.002 (-0.46%)
AZN : 76.90 (-0.18%)
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Newswire.ca - Wed Jun 28, 2023

/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...

BLU : 14.74 (unch)
GSK.LN : 1,775.000 (-0.48%)
GSK : 44.98 (+0.22%)
BLU.TO : 19.48 (-0.10%)
Author
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results MarketBeat - Mon May 8, 2023

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

SGEN : 228.74 (-0.07%)
AZN : 76.90 (-0.18%)
IMGN : 31.23 (unch)
GSK : 44.98 (+0.22%)
GSK.LN : 1,775.000 (-0.48%)
PFE : 28.64 (-0.97%)
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment ACN Newswire - Thu May 4, 2023

International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment

FOSUF : 0.5350 (+1.94%)
FOSUY : 14.5300 (+1.25%)
GSK.LN : 1,775.000 (-0.48%)
GSK : 44.98 (+0.22%)
JNJ : 154.64 (+0.23%)
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health Business Wire - Tue Apr 18, 2023

GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical...

BLU : 14.74 (unch)
GSK : 44.98 (+0.22%)
GSK.LN : 1,775.000 (-0.48%)
BLU.TO : 19.48 (-0.10%)
Author
Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging MarketBeat - Mon Apr 10, 2023

While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat

IBM : 169.03 (+0.04%)
GOOG : 177.29 (+1.06%)
GOOGL : 176.06 (+1.08%)
GM : 45.76 (-0.24%)
GMM-U.TO : 43.32 (-1.23%)
GSK : 44.98 (+0.22%)
GSK.LN : 1,775.000 (-0.48%)
MSFT : 420.21 (-0.19%)
WWE : 100.65 (+2.65%)
Author
Schrodinger is an AI-Powered Drug Discovery Developer to Watch MarketBeat - Wed Mar 8, 2023

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117

SDGR : 22.76 (-0.61%)
AZN.LN : 12,110.002 (-0.46%)
AZN : 76.90 (-0.18%)
AZNCF : 155.2600 (-0.30%)
LLY : 770.00 (-0.15%)
GSK : 44.98 (+0.22%)
GSK.LN : 1,775.000 (-0.48%)
ON : 73.17 (+0.23%)
PFE : 28.64 (-0.97%)
MRK : 131.19 (+0.24%)

Barchart Exclusives

Microsoft Still Looks Cheap, Worth 26% More Based on its FCF - Good for Short Put Income Plays Barchart - 22 minutes ago
Microsoft stock still looks cheap based on its huge AI focus and FCF margins. It could be worth up to $529 per share, +26%. Existing shareholders can make extra income shorting out-of-the-money put options. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot